What's new

[Cyprus Times] Truth be told

thumbnail_Dr-Androulla-Eleftheriou.jpg

A new round of controversy has opened in recent days in the health sector with a "war" of announcements between the Ministry of Health and the Health Insurance Organisation (HIO) regarding the not so desirable issues of referring patients abroad or to private, non-GESY, hospitals, as well as the provision to patients of drugs not currently covered by the HIO.

The budget of EUR 123 million referred to is indeed prohibitive, but it is beyond my knowledge and competence to assess whether it is appropriate or not as a requirement for the provision of the above services.

What I am able and obliged to position myself on as a former President and one of the founders of the Pancyprian Alliance for Rare Diseases and in my current capacity of Executive Director of the International Thalassaemia Federation, is the serious barriers that patients with rare and other chronic complex and degenerative diseases face in accessing appropriate treatments and medication in our country.

It is precisely this complexity in pathology that characterises mainly, but not exclusively, rare diseases that is the reason why not only the treatment of sufferers, where it exists and is feasible, with a range of "orphan", as they are called, particularly high cost drugs, but also special expertise and multidisciplinarity in their management and treatment, characteristics in which Cyprus, not unfairly as a small state, lags dramatically behind compared to other foreign countries.

I have experienced first-hand the "diagnostic and therapeutic odyssey" that many of these people go through and have witnessed the failings of the health sector to provide them with a decent living, despite the improvements that have been achieved with the creation of the GHS. Therefore, I must say that the efforts made in recent years by the Ministry of Health, the General Directorate of the Ministry and Mrs. Giannakis personally, both to serve patients by referring them to centres abroad, and to address the gaps that exist at the internal level, are remarkable.

Thanks to the procedures, regulations and protocols that have been promoted, patients who until recently had no way of timely and coordinated access to specialised treatments and innovative therapies, have been able to benefit from the services provided by the Health Ministry. So I am here to report in all honesty my own experience of serving dozens of patients through this programme. If this project should now be included in the services offered by the OAS, of course it should, but with coordinated actions, proper preparation and the necessary, properly trained, staff.

We are at a critical crossroads that will largely determine the future course of the GHS. A system that we have fought tooth and nail to implement and whose benefits to society have been tremendous.

We must all together, with the responsibility resting first and foremost with the decision-makers, demand and achieve in practice full transparency in all procedures concerning the management of health sector expenditure, both within and outside the GHS, and above all the qualitative upgrading of the system, components that will undoubtedly contribute to limiting the waste of public money. At the same time, the OAI should work at a faster pace to integrate more services and provisions into the GHS in a rational manner for the benefit of timely and efficient patient care.



Time is counting down and it is not on our side.

*Dr. Androulla Eleftheriou

Biologist BSC, MSc, PhD

Executive Director of the International Thalassaemia Federation (IOF)


Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times

Source

 
Back
Top